Allogeneic hematopoietic cell transplantation (allo-HCT) and chimeric antigen receptor T cell (CAR T) therapy are the main modalities of adoptive cellular immunotherapy that have widely permeated the clinical space.

2024年11月22日 · 国内学者开展回顾性研究，分析了中国四家医院的21例复发或难治性（R/R）成人BL患者接受CAR-T治疗±造血细胞移植（HCT）的结果，证实通过auto-HCT联合CAR-T细胞治疗可实现长期疾病控制，且该研究首次证实R/R BL获得如此长的无病生存，近日发表于 …

This study retrospectively analyzed the outcomes of 21 relapsed or refractory (R/R) adult BL patients treated with chimeric antigen receptor T-cell (CAR-T) therapy, combined or not with hematopoietic cell transplantation (HCT), across four Chinese hospitals.

2022年11月2日 · AutoHCT allows for hematopoietic rescue following the administration of high-dose, myeloablative chemotherapy, predominantly in multiple myeloma, relapsed lymphomas, and germ cell tumors. 1 In contrast, AlloHCT exploits not only cytotoxic chemotherapy but also the immunotherapeutic graft-versus-tumor effect from adoptive transfer of a donor immu...

Cellular therapy modalities, including autologous (auto-) hematopoietic cell transplantation (HCT), allogeneic (allo-) HCT, and now chimeric antigen receptor (CAR) T cell therapy, have demonstrated long-term remission in advanced hematologic malignancies.

2022年5月16日 · 总的来说，auto-hsct后进行car-t治疗可以结合两者的优势，即大剂量化疗降低肿瘤负荷和car-t细胞消除残留恶性肿瘤细胞的抗肿瘤疗效靶点，且car-t仍可保留残留的car-t细胞以维持抗肿瘤疗效。

2024年7月8日 · In patients with relapsed DLBCL in complete remission (CR), autologous hematopoietic cell transplantation (auto-HCT) and CAR-T therapy are both effective, but it is unknown which modality...

复发限制了嵌合抗原受体 (car) t 细胞和同种异体造血细胞移植 (allo-hct) 的治疗效果。患者可以依次接受这些治疗以预防或治疗复发性恶性肿瘤。然而，由于担心同种异体 car t 细胞可能诱发移植物抗宿主病 (gvhd)，因此避免了两种疗法的直接整合。我们在小鼠 t 细胞充满 mhc 单倍体同种异体 …

2024年4月25日 · Our findings suggest that sequential CD7 CAR T-cell therapy and haploidentical HSCT is safe and effective, with remission and serious but reversible adverse events. This strategy offers a feasible approach for patients with CD7-positive tumors who are ineligible for conventional allogeneic HSCT.

In 2022, 46,143 HCT (19,011 (41.2%) allogeneic and 27,132 (58.8%) autologous) in 41,854 patients were reported by 689 European centers. 4329 patients received advanced cellular therapies, 3205 of...